Author of

• 30292

  +

  EP1.01 - Advanced NSCLC (ID 150)

  • Event: WCLC 2019
  • Type: E-Poster Viewing in the Exhibit Hall
  • Track: Advanced NSCLC
  • Presentations: 1
  • Now Available
  • Moderators:
  • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall

  • 30310

    +

    EP1.01-14 - The Scour Using Pretreatment NLR, Liver Metastasis, PD-L1 Status and PS as a Marker of Outcomes in Nivolumab-Treated Patients with Advanced NSCLC (Now Available) (ID 884)

    08:00 - 18:00  |  Author(s): Takayuki Shiroyama
    • Abstract
    • Slides

    Background
    

    Although nivolumab showed the significantly longer overall survival (OS) compared with docetaxel for non-small cell lung cancer (NSCLC) based on two phase III randomized controlled trials, programed death ligand 1 (PD-L1) expression alone is not yet an adequate biomarker in treating nivolumab for NSCLC patients. Furthermore, some prior analyses indicated the liver metastasis, performance status (PS) and pretreatment neutrophil-to-lymphocyte ratio (NLR) is one of the candidates of effect predictors. This retrospective study aimed to analyze the score combining pretreatment patients’ status as a predictive marker in NSCLC patients treated with nivolumab.

    Method
    

    ne hundred and twenty-eight patients treated with Nivolumab who could examine the PD-L1 status from December 2015 to July 2016 were retrospectively reviewed. This study was multicenter study conducted by the three respiratory medical centers in Japan. We collected clinical data including age, sex, smoking history, histological types, PS, NLR, existence of Liver metastasis and PD-L1 status. We made the predictive score (PS2-4: 3 points, >NLR 4: 1 point, Liver metastasis +: 1 point, PD-L1 0%: 1 point and over 50%: -1 point) from pretreatment patients’ characteristics and evaluate the score (over 4 points is high risk group, 2-3 points is mediate risk group, and under 1 point is low risk group) as a marker of outcomes. The data cut off was on 31^th October 2017.

    Result
    

    Median age was 67 years old, 86 patients were male, 101 patients had smoking history, 99 patients were PS 0-1 and 29 patients were PS 2-4, 26 patients were squamous carcinoma, >NLR 4 were 48 patients, and 16 patients had liver metastasis, respectively. Furthermore, PD-L1 expression 0% were 62 patients, 1-49% were 42 patients, and over 50% were 24 patients.

    Progression disease rate, median progression free survival (PFS) and median OS was 61.1%, 1.1 months, 2.4 months in high risk group; 60.6%, 1.4 months, 10.9 months in mediate risk group; and 36.4%, 4.6 months, 16.3 months in low risk group, respectively.

    Conclusion
    

    We could classify the three group which could predict an patients’ outcome according to the patients’ characteristics.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.